Bayer Says Aurobindo’s Launch of Xarelto Copies Defied Pact

Aurobindo Pharma Ltd.’s April launch of its copy of the blockbuster blood thinner Xarelto violated a confidential patent settlement it reached last year with Bayer AG and Johnson & Johnson’s Janssen unit, according to a federal lawsuit.

The drugmakers’ sealed complaint was docketed Thursday in the US District Court for the District of Delaware. It accused Aurobindo of breaking the May 2024 settlement by selling generic versions of Xarelto’s 2.5-milligram tablets shortly after the US Food and Drug Administration approved its copies April 10, according to a concurrent motion for leave to file the complaint under seal. Bayer and Janssen ...